ライフサイエンスコーパス: antibacterial agent

1 tivity showed that CC extract is a potential antibacterial agent.

2 s the potential to be developed into a novel antibacterial agent.

3 indicating its potential applications as an antibacterial agent.

4 dant activities, but it was not effective as antibacterial agent.

5 ons of materials impregnated with a leaching antibacterial agent.

6 dant activities, but it was not effective as antibacterial agent.

7 is approach to prepare racemic linezolid, an antibacterial agent.

8 s used, suggesting that it can be used as an antibacterial agent.

9 indicating its potential as a cross-species antibacterial agent.

10 ocarban and triclosan, another commonly used antibacterial agent.

11 lidixic acid (NAL), a recalcitrant quinolone antibacterial agent.

12 interactions and are established targets for antibacterial agents.

13 s of the LPS and their role in resistance to antibacterial agents.

14 of action could be exploited to develop new antibacterial agents.

15 al ribosome makes it an important target for antibacterial agents.

16 zed cells only to josamycin but not to other antibacterial agents.

17 ction models that was comparable to marketed antibacterial agents.

18 ultimately approval of critically needed new antibacterial agents.

19 attractive target for the development of new antibacterial agents.

20 , and their biosynthesis is a target for new antibacterial agents.

21 ew target are not cross-resistant with other antibacterial agents.

22 help to fill the growing unmet need for new antibacterial agents.

23 ch attention as a potential target for novel antibacterial agents.

24 inhibitors for HMM PBPs as HMM PBP targeted antibacterial agents.

25 e biochemical tools and attractive potential antibacterial agents.

26 se is an attractive target for the design of antibacterial agents.

27 in directly assessing D-Ala branch targeted antibacterial agents.

28 xicity, KdsC is a potential target for novel antibacterial agents.

29 cell surface represents a distinct class of antibacterial agents.

30 hat Gcp may be a novel target for developing antibacterial agents.

31 nexploited target for the development of new antibacterial agents.

32 iotics demonstrates the medical need for new antibacterial agents.

33 unnatural oligomers intended to function as antibacterial agents.

34 nones represent a new and promising class of antibacterial agents.

35 s of the MazEF interaction have potential as antibacterial agents.

36 thus an attractive target for developing new antibacterial agents.

37 lopyridones and their in vitro evaluation as antibacterial agents.

38 g to the use of purified phage components as antibacterial agents.

39 targets for the discovery and development of antibacterial agents.

40 ion and potentially provide a novel class of antibacterial agents.

41 en identified as an appealing new target for antibacterial agents.

42 or antibiotic discovery and developing novel antibacterial agents.

43 ttractive targets for the development of new antibacterial agents.

44 otential target for the development of novel antibacterial agents.

45 r developing highly specific and efficacious antibacterial agents.

46 plex should be candidates as leads for novel antibacterial agents.

47 ay have utility for the development of novel antibacterial agents.

48 n and suggest strategies for design of novel antibacterial agents.

49 r developing highly specific and efficacious antibacterial agents.

50 ds for the development of new broad-spectrum antibacterial agents.

51 fflux pump AcrAB-TolC expels a wide range of antibacterial agents.

52 ginosa-specific quorum-sensing inhibitors as antibacterial agents.

53 genesis and opens a new venue for developing antibacterial agents.

54 of small molecules, including nutrients and antibacterial agents.

55 droxyethyl)pyrrolidine-2,4-dione, are potent antibacterial agents.

56 herefore represents an attractive target for antibacterial agents.

57 a potential target for development of novel antibacterial agents.

58 were inactive as either enzyme inhibitors or antibacterial agents.

59 tudies on NAD synthetase as a new target for antibacterial agents.

60 tractive target for the development of novel antibacterial agents.

61 llenged by resistance to currently available antibacterial agents.

62 l enoyl-ACP reductases are valid targets for antibacterial agents.

63 tentially viable strategy for developing new antibacterial agents.

64 d perhaps even to develop novel FHA-blocking antibacterial agents.

65 asis for the development of new PBP-targeted antibacterial agents.

66 attractive target for the development of new antibacterial agents.

67 get ribosomal RNA and uncover a new class of antibacterial agents.

68 to be valuable targets for identifying novel antibacterial agents.

69 nce in patients with type II diabetes and as antibacterial agents.

70 utilized for the identification of potential antibacterial agents.

71 h the bacterial toxin CcdB and the quinolone antibacterial agents.

72 cell wall biosynthesis and discovery of new antibacterial agents.

73 riophages to increase their effectiveness as antibacterial agents.

74 ent the first examples of H. pylori-specific antibacterial agents.

75 specific deformylase inhibitors as potential antibacterial agents.

76 recipients should include antifungal and not antibacterial agents.

77 ntriguing targets for the development of new antibacterial agents.

78 ch can be optimized to design more selective antibacterial agents.

79 tial in prokaryotes, it is a good target for antibacterial agents.

80 eloping phage into therapeutically effective antibacterial agents.

81 dylate synthase (TS) and as antitumor and/or antibacterial agents.

82 ance studies, and support development of new antibacterial agents.

83 BMSCs also make antibacterial agents.

84 otic, thus urging for the discovery of novel antibacterial agents.

85 viruses, called bacteriophages or phages, as antibacterial agents.

86 ection sites, thus enhancing the delivery of antibacterial agents.

87 tics as well as a lack of development of new antibacterial agents.

88 discovery and development efforts toward new antibacterial agents.

89 y is one of the most important properties of antibacterial agents.

90 biotic overuse compel us to seek alternative antibacterial agents.

91 ultimately approval of critically needed new antibacterial agents.

92 ides a paradigm shift towards development of antibacterial agents.

93 rganisms in order to preserve the utility of antibacterial agents.

94 received considerable interest as potential antibacterial agents.

95 ys should guide designs of new mineral-based antibacterial agents.

96 ides (AMPs) should help in the design of new antibacterial agents.

97 n mechanism and discovery of target-specific antibacterial agents.

98 argets for the design and development of new antibacterial agents.

99 undamental importance to efforts to discover antibacterial agents.

100 ell as identifying candidate targets for new antibacterial agents.

101 tanding of the development of broad-spectrum antibacterial agents.

102 is challenge will require development of new antibacterial agents.

103 idated for the evaluation of the efficacy of antibacterial agents.

104 suitable platform for future development of antibacterial agents.

105 as promising candidates in the market as new antibacterial agents.

106 traits, such as virulence and resistance to antibacterial agents.

107 actams, 10 on glycopeptides, and 12 on other antibacterial agents.

108 er development of this class of compounds as antibacterial agents.

109 in particular is a well-validated target for antibacterial agents.

110 Bacterial methylation of an antibacterial agent, 14, catalyzed by Rv0560c of Mtb, is

111 aluation of a new generation of tetracycline antibacterial agents, 7-fluoro-9-substituted-6-demethyl-

112 creases resistance to two positively charged antibacterial agents, a beta-lactam and high concentrati

113 xazolidinones are a novel class of synthetic antibacterial agents active against gram-positive organi

114 se with the potential to be novel and potent antibacterial agents active against pathogenic bacteria.

115 The role of prophylactic antibacterial agents after chemotherapy remains controve

116 similar potency to the natural product as an antibacterial agent against a variety of strains, includ

117 s that TA is the major M. xanthus-diffusible antibacterial agent against E. coli.

118 C (VitC), a natural antioxidant as powerful antibacterial agent against multidrug-resistant (MDR), b

119 tructure-based drug design of a new class of antibacterial agents against a clinically proven, but co

120 vitro activity of ceftaroline and comparator antibacterial agents against ABSSSI and CABP pathogens.

121 rategy that enables the development of novel antibacterial agents against clinically relevant Gram-ne

122 and 3 warrant further investigation as novel antibacterial agents against drug-resistant enterococci.

123 These compounds were found to be potent antibacterial agents against Gram-positive organisms in

124 vitro activity of ceftaroline and comparator antibacterial agents against invasive respiratory isolat

125 (MenA) inhibitors 1a and 2a act as selective antibacterial agents against organisms such as methicill

126 lop selective class II inhibitors for use as antibacterial agents against pathogenic microorganisms.

127 erence method to assess in vitro activity of antibacterial agents against which both novel agents and

128 ued in parallel, including 'non-traditional' antibacterial agents (agents that are not small-molecule

129 orts to discover advanced and cost effective antibacterial agents among the ever-increasing PA bacter

130 fore, identifying an effective antibiotic or antibacterial agent and administering it at concentratio

131 should be informative in the search for new antibacterial agents and drug targets.

132 phages because of their potential for use as antibacterial agents and for their ecological roles in b

133 splays little cross-resistance with marketed antibacterial agents and is active against methicillin-r

134 l wall biosynthesis is the target of several antibacterial agents and is also of interest as a target

135 uity, rigor, and generalizability in RCTs of antibacterial agents and reduce health inequities.

136 en developed without the use of any external antibacterial agents and surface treatments.

137 selves in a continual battle to identify new antibacterial agents and targets.

138 ween the physicochemical properties of known antibacterial agents and the HTS active starting point,

139 , which had not previously been evaluated as antibacterial agents and were found to be potent inhibit

140 sisting of sulfapyridine, a sulfa-containing antibacterial agent, and 5-amino-salicylate (5-ASA), an

141 ple organ failure, exposed to broad-spectrum antibacterial agents, and enrolled between July 2012 and

142 gnostic studies, decreasing empirical use of antibacterial agents, and facilitating early identificat

143 is a problem that is often encountered with antibacterial agents, and it is also an issue with antif

144 arget for reversal of resistance to selected antibacterial agents, and recently we described indole-b

145 rapeutic target for the development of novel antibacterial agents, and we continue to explore TMK inh

146 Several new antibacterial agents are currently being developed in re

147 At least 18 antibacterial agents are currently undergoing clinical t

148 A number of new antibacterial agents are in late stage clinical developm

149 ces from the human FAS, and several existing antibacterial agents are known to inhibit FASII enzymes.

150 Novel antibacterial agents are needed to address the emergence

151 As novel antibacterial agents are urgently needed, we re-assessed

152 Silver nanoparticles (AgNPs), an effective antibacterial agent, are a significant and fast-growing

153 e of our investigations in the oxazolidinone antibacterial agent area, we have identified a subclass

154 for further development of borinic esters as antibacterial agents as well as leads to explore more sp

155 identified actinonin, a naturally occurring antibacterial agent, as a potent PDF inhibitor.

156 Among the targets for the development of new antibacterial agents, bacterial topoisomerases remain a

157 Novel quinolone antibacterial agents bearing (3S)-amino-(4R)-ethylpiperi

158 rly suitable for targeting by broad-spectrum antibacterial agents because due to the slow evolutionar

159 Fluoroquinolones are potent antibacterial agents being used clinically against multi

160 tical not only in designing newer-generation antibacterial agents but also in providing insight into

161 in the development and marketing of over 100 antibacterial agents but, with the exception of the oxaz

162 s) are widely used in commercial products as antibacterial agents, but AgNPs might be hazardous to th

163 protein, Siderocalin (Scn), which acts as an antibacterial agent by specifically sequestering siderop

164 san (LMWC) and nisin, recognized as cationic antibacterial agents (CAAs), inhibit bacterial growth by

165 nt studies have shown that the activities of antibacterial agents can be enhanced through complexatio

166 Antibiotic resistance and the lack of new antibacterial agents cause major challenges for the trea

167 such as the natural product nitrofungin, the antibacterial agent chloroxylenol, and the herbicide chl

168 ions that confer resistance to the quinolone antibacterial agents cluster at the new dimer interface,

169 A new and promising group of antibacterial agents, collectively known as the oxazolid

170 nto target-based approaches to produce novel antibacterial agents, companies large and small have exi

171 nd libraries led to the discovery of a novel antibacterial agent, compound 1 (MIC: 12-25 microM again

172 ew target is different from targets of other antibacterial agents, compounds that bind to the new tar

173 The antibacterial agents currently in clinical development a

174 Several other classes of antibacterial agents currently in clinical trials are re

175 d is also of interest as a target for future antibacterial agent development.

176 oA reductases thus are potential targets for antibacterial agents directed against multidrug-resistan

177 and for the discovery and development of new antibacterial agents directed toward novel targets.

178 in the analytical methodology available for antibacterial agent discovery and characterization.

179 otential target for the development of novel antibacterial agents due to its unique physiological and

180 the biosynthetic pathway for the widely used antibacterial agent erythromycin.

181 d that cells treated with josamycin or other antibacterial agents exhibited impaired oxidative phosph

182 levels; (b) NaOCl is shown as the strongest antibacterial agent for the oral biofilms; (c) multispec

183 y of gepotidacin, a new triazaacenaphthylene antibacterial agent for the treatment of conventional an

184 s inhibitors of NAD synthetase and as potent antibacterial agents for Gram-positive strains.

185 ic analogues have been among the most useful antibacterial agents for the treatment of infectious dis

186 vice database were analyzed, with a focus on antibacterial agents from 2001 to 2013.

187 osed to a subinhibitory concentration of the antibacterial agent, glyphosate.

188 This parenteral antibacterial agent has a dual mechanism of action and p

189 Target-based screening for new antibacterial agents has been particularly disappointing

190 en-carbon-linked (azolylphenyl)oxazolidinone antibacterial agents has been prepared in an effort to e

191 bined with the decline in discovery of novel antibacterial agents has created a global public health

192 enzymes by actinonin, a naturally occurring antibacterial agent, has been characterized using steady

193 Antibacterial agents have been historically studied in n

194 Several antibacterial agents have been studied as a means to pro

195 Traditionally, antibacterial agents have been studied in noninferiority

196 Silver-based antibacterial agents have obtained wide attention due to

197 ones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action w

198 The pathogen, with its susceptibility to an antibacterial agent (ie, pharmacodynamics [PD]), is a gi

199 cture of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureu

200 Triclocarban is widely used as an antibacterial agent in personal care products, and the p

201 iology, suggest that phages may be useful as antibacterial agents in certain conditions.

202 tribute to the fate and transport of OA-type antibacterial agents in marine sediments and waters.

203 continued need for innovation and new-class antibacterial agents in order to provide effective thera

204 sitive nanoplatforms can selectively release antibacterial agents in the acidic environment of infect

205 elationships have been found among macrolide antibacterial agents in their potencies against the bact

206 3-anhydro macrolides were found to be potent antibacterial agents in vitro against macrolide-suscepti

207 The bacillus is susceptible to several antibacterial agents in vitro, including penicillins, ce

208 romised the effectiveness of most classes of antibacterial agent, including the classes that target t

209 ibe studies leading to the identification of antibacterial agents incorporating a novel isoxazoline A

210 Rifamycin antibacterial agents inhibit bacterial RNA polymerase (R

211 in pathogens necessitates the development of antibacterial agents inhibiting underexplored targets in

212 ch programs involved in the discovery of new antibacterial agents inspired by a diverse series of nat

213 he primary target for the quinolone group of antibacterial agents is DNA gyrase.

214 ns, and resistance to virtually all approved antibacterial agents is emerging in this pathogen.

215 novative combination approaches and/or novel antibacterial agents is occurring in the context of redu

216 this problem is encountered more often with antibacterial agents, it is also an issue with antifunga

217 ontinue to be actively developed as clinical antibacterial agents, largely owing to the success of th

218 olide, and nonylphenol are representative of antibacterial agents, nitro-musks, and surfactants, resp

219 It is disturbing that the antibacterial agents of the most advanced type, which ar

220 Natural and synthetic membrane active antibacterial agents offer hope as potential solutions t

221 Their development as novel antibacterial agents offers many potential advantages ov

222 functional component (ripening inhibitor and antibacterial agent) on the formation, stability and ant

223 No inhibition by antibacterial agents or disinfectants from the hospital

224 wing concern due to a striking lack of novel antibacterial agents over the course of the last decades

225 the small-molecule cell-cycle inhibitor and antibacterial agent PC190723 that targets FtsZ.

226 predominantly used for invasive candidiasis, antibacterial agents posing the highest risk for Clostri

227 charged AgNPs may serve as a next-generation antibacterial agent, potentially addressing the rising H

228 The successful preparation of an antibacterial agent precursor was also investigated.

229 Microcin C (McC) is a potent antibacterial agent produced by some strains of Escheric

230 Unlike most antibacterial agents, PZA, despite its remarkable in viv

231 yridine derivatives are potent cytotoxic and antibacterial agents, respectively.

232 From a public health perspective, new antibacterial agents should be evaluated and approved fo

233 upported effort, yielding a unique series of antibacterial agents showing a novel, induced-fit bindin

234 lyfunctional amines has led to new macrolide antibacterial agents, some of which are highly potent ag

235 noquinzolinediones represent a new series of antibacterial agents structurally related to the fluoroq

236 Dental composites releasing antibacterial agents such as chlorhexidine (CHX) have sh

237 veral potential advantages over conventional antibacterial agents such as host specificity, self-ampl

238 Quinolones linked to other antibacterial agents such as rifamycins and oxazolidinon

239 cent increase in research into orally active antibacterial agents, such as carbapenems and cephalospo

240 Antibacterial agents target the products of essential ge

241 Various antitumor and antibacterial agents target type II DNA topoisomerases,

242 ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorr

243 all aminoglycoside neamine as broad spectrum antibacterial agents targeting bacterial membranes.

244 here should be useful for the development of antibacterial agents targeting TMK without undesired off

245 mbda mutants also have greater capability as antibacterial agents than the corresponding parental str

246 er, and yet equipotent, or even more potent, antibacterial agents than the natural product, thereby s

247 AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials

248 Triclosan is a broad-spectrum antibacterial agent that inhibits bacterial fatty acid s

249 Ceftaroline is a new antibacterial agent that is active against the major bac

250 cin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial

251 first member of a promising, novel class of antibacterial agents that act by inhibiting bacterial DN

252 or testing the susceptibility of bacteria to antibacterial agents that affect their cell wall.

253 inones are a new chemical class of synthetic antibacterial agents that are active orally or intraveno

254 e are of interest for the development of new antibacterial agents that are impacted by target-mediate

255 y applied to the discovery of in vivo active antibacterial agents that are inhibitors of bacterial pe

256 ) are of interest for the development of new antibacterial agents that are not impacted by target-med

257 Fluoroquinolones are antibacterial agents that attack DNA gyrase and topoisom

258 ry bacterium, making it a logical target for antibacterial agents that can convert the enzyme into po

259 idence time and the potential development of antibacterial agents that cause prolonged suppression of

260 this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow

261 e sought to define feasible trial designs of antibacterial agents that could enable conduct of superi

262 eptide (ADEP) antibiotics are a new class of antibacterial agents that kill bacteria via a mechanism

263 benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA g

264 ngs provide scope for the development of new antibacterial agents that prevent DAPDC dimerization.

265 Quinolones are potent antibacterial agents that specifically target bacterial

266 ound approaches (products other than classic antibacterial agents) that target bacteria or any approa

267 e is the target for the diazaborine class of antibacterial agents, the biocide triclosan, and one of

268 Despite treatment with antifungal and antibacterial agents, the patient developed progressive

269 ready been established as a target for novel antibacterial agents through suicide inactivation by a n

270 tion of repurposing simvastatin as a topical antibacterial agent to treat skin infections.

271 e molecules as candidates for a new class of antibacterial agents to combat antimicrobial-resistant b

272 The development of new antibacterial agents to combat worsening antibiotic resi

273 m can be addressed by the development of new antibacterial agents to keep pace with the evolutionary

274 ntly investigated for the discovery of novel antibacterial agents to prevent or treat infections caus

275 nones represent the first truly new class of antibacterial agents to reach the marketplace in several

276 New antibacterial agents to treat infections caused by antib

277 a critical need for new pathways to develop antibacterial agents to treat life-threatening infection

278 rsists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-

279 y prevalence in children and exposure to the antibacterial agent triclosan and having filaggrin (FLG)

280 enzyme for folate antagonists, including the antibacterial agent trimethoprim (TMP).

281 an R-plasmid, that confers resistance to the antibacterial agent trimethoprim.

282 ng the benefits and harms of a controversial antibacterial agent undergo change when passed from one

283 rylate (DMADDM) is a well-studied and potent antibacterial agent used in various studies described in

284 The therapeutic application of phages as antibacterial agents was impeded by several factors: (i)

285 In an effort to find nontraditional antibacterial agents, we previously designed peptides fr

286 biotics including antiviral, antifungal, and antibacterial agents were administered during the treatm

287 s largely based on retrospective analyses of antibacterial agents, which suggest that polarity and mo

288 otoswitchable antibiotics, we introduce here antibacterial agents whose activity can be controlled by

289 ective control of cytokine concentrations by antibacterial agents will clearly have important therape

290 f biological activity surfacing as an active antibacterial agent with an intriguing mode of action.

291 se synergistic roles for human SPLUNC1 as an antibacterial agent with bacteriostatic and chemotactic

292 een used clinically, although it is a potent antibacterial agent with low toxicity (Therapeutic Index

293 In order to develop a potent antibacterial agent with the desired spectrum of activit

294 ocycle provide a new class of broad-spectrum antibacterial agents with activity against MDR Gram-nega

295 te model should facilitate the design of new antibacterial agents with improved activity against S. p

296 ed. HGFs were exposed to serial dilutions of antibacterial agents with media.

297 d, and several of these compounds are potent antibacterial agents with minimum inhibitory concentrati

298 New antibacterial agents with novel actions are vital to tre

299 The discovery of new antibacterial agents with novel mechanisms of action is

300 d enabling their discovery as broad-spectrum antibacterial agents, with promising activity against bo